SearchDictionaryMobileLogin

F C Breedveld Selected Research

Rheumatoid Arthritis

06/2008Value of serum cartilage oligomeric matrix protein as a prognostic marker of large-joint damage in rheumatoid arthritis--data from the RAPIT study.
05/2008Progression of joint damage in early rheumatoid arthritis: Association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies.
08/2007Ex vivo interleukin 1 receptor antagonist production on lipopolysaccharide stimulation is associated with rheumatoid arthritis and with joint damage.
07/2007Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis.
02/2007Consensus statement on the use of rituximab in patients with rheumatoid arthritis.
12/2006Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response.
10/2006CTLA-4IG suppresses reactive oxygen species by preventing synovial adherent cell-induced inactivation of Rap1, a Ras family GTPASE mediator of oxidative stress in rheumatoid arthritis T cells.
03/2006Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles.
08/2005Long-term followup of health status in patients with severe rheumatoid arthritis after high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation.
04/2005Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.
01/2005Association between baseline radiographic damage and improvement in physical function after treatment of patients with rheumatoid arthritis.
09/2004Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis.
06/2004Nutrient supplementation with polyunsaturated fatty acids and micronutrients in rheumatoid arthritis: clinical and biochemical effects.
05/2004T cells, fibroblast-like synoviocytes, and granzyme B+ cytotoxic cells are associated with joint damage in patients with recent onset rheumatoid arthritis.
04/2004Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate.
03/2004Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study.
02/2004Infliximab in active early rheumatoid arthritis.
01/2004Rapid alleviation of signs and symptoms of rheumatoid arthritis with intravenous or subcutaneous administration of adalimumab in combination with methotrexate.
12/2003Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study.
09/2003A proposed treatment algorithm for rheumatoid arthritis: aggressive therapy, methotrexate, and quantitative measures.
07/2003Analysis of the cell infiltrate and expression of proinflammatory cytokines and matrix metalloproteinases in arthroscopic synovial biopsies: comparison with synovial samples from patients with end stage, destructive rheumatoid arthritis.
07/2003Association of the -2849 interleukin-10 promoter polymorphism with autoantibody production and joint destruction in rheumatoid arthritis.
05/2003No therapeutic effect of plasmin antagonist tranexamic acid in rheumatoid arthritis. A double-blind placebo-controlled pilot study.
02/2003Human IgG Fc-binding phage antibodies constructed from synovial fluid CD38+ B cells of patients with rheumatoid arthritis show the imprints of an antigen-dependent process of somatic hypermutation and clonal selection.
12/2002Polyreactivity of human IgG Fc-binding phage antibodies constructed from synovial fluid CD38+ B cells of patients with rheumatoid arthritis.
04/2002Early and aggressive treatment of rheumatoid arthritis patients affects the association of HLA class II antigens with progression of joint damage.
02/2002Relationship of polymorphisms of the Interleukin-1 gene cluster to occurrence and severity of rheumatoid arthritis.
11/2001Human leukocyte antigen-DQ and DR polymorphisms predict rheumatoid arthritis outcome better than DR alone.
10/2001Is there a place for leflunomide in the treatment of rheumatoid arthritis?
10/2001Intensive immunosuppression and autologous stem cell transplantation for patients with severe rheumatoid arthritis: the Leiden experience.
09/2001[Treatment of rheumatoid arthritis by inhibition of tumor necrosis factor with infliximab or etanercept]
07/2001Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study.
05/2001Allele-specific quantification of tumor necrosis factor alpha (TNF) transcription and the role of promoter polymorphisms in rheumatoid arthritis patients and healthy individuals.
04/2001High-dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with rheumatoid arthritis: results of an open study to assess feasibility, safety, and efficacy.
02/2001Evidence for a protective role of the human leukocyte antigen class II region in early rheumatoid arthritis.
01/2001Secretion of anti-citrulline-containing peptide antibody by B lymphocytes in rheumatoid arthritis.
01/2001Human granzyme B mediates cartilage proteoglycan degradation and is expressed at the invasive front of the synovium in rheumatoid arthritis.
12/2000Cellular immune response to human cartilage glycoprotein-39 (HC gp-39)-derived peptides in rheumatoid arthritis and other inflammatory conditions.
11/2000Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
11/2000Leflunomide: mode of action in the treatment of rheumatoid arthritis.
08/2000Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers.
07/2000Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis: findings in a prospective, randomized, double-blind clinical trial in fifteen patients.
07/2000Raised human cartilage glycoprotein-39 plasma levels in patients with rheumatoid arthritis and other inflammatory conditions.
05/2000Methotrexate effects in patients with rheumatoid arthritis with cardiovascular comorbidity.
05/2000Regulation of synovial B cell survival in rheumatoid arthritis by vascular cell adhesion molecule 1 (CD106) expressed on fibroblast-like synoviocytes.
03/2000Presence of bacterial DNA and bacterial peptidoglycans in joints of patients with rheumatoid arthritis and other arthritides.
02/2000The effects of interferon-beta treatment of synovial inflammation and expression of metalloproteinases in patients with rheumatoid arthritis.
01/2000Influence of blood and synovial fluid immune complexes of patients with rheumatoid arthritis on production of nitric oxide and growth and viability of chondrocytes.
01/2000The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide.

Articles by Research Topic

Disease

49Rheumatoid Arthritis
06/2008 - 01/2000
5Arthritis (Polyarthritis)
09/2008 - 03/2000
5Necrosis
08/2008 - 12/2003
3Systemic Scleroderma (Systemic Sclerosis)
08/2004 - 12/2000
3Inflammation
01/2001 - 02/2000
2Rheumatic Diseases (Rheumatism)
11/2005 - 11/2004
1Knee Osteoarthritis
08/2008
1Osteoarthritis
04/2005
1Tuberculosis
04/2003
1Skin Diseases
06/2001
1Systemic Lupus Erythematosus (Libman-Sacks Disease)
01/2000

Drug/Important Bio-Agent (IBA)

11Methotrexate (Mexate)FDA LinkGeneric
07/2007 - 05/2000
7infliximab (Remicade)FDA Link
07/2007 - 11/2000
6AntibodiesIBA
05/2008 - 01/2000
6Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
11/2005 - 11/2000
5leflunomide (Arava)FDA LinkGeneric
09/2004 - 07/2000
3Interleukin-1 (Interleukin 1)IBA
11/2005 - 02/2002
3adalimumab (Humira)FDA Link
10/2005 - 12/2003
2Adrenal Cortex Hormones (Corticosteroids)IBA
09/2008 - 12/2006
2Interleukin-10 (Interleukin 10)IBA
08/2008 - 07/2003
2HLA-DRB1 antigen (HLA DRB1)IBA
05/2008 - 03/2006
2cyclic citrullinated peptideIBA
12/2006 - 01/2000
2TNFR-Fc fusion protein (etanercept)FDA Link
10/2005 - 09/2001
2Granzymes (Granzyme)IBA
05/2004 - 01/2001
2PeptidesIBA
03/2004 - 12/2000
2Immunoglobulin G (IgG)IBA
02/2003 - 12/2002
2AntigensIBA
02/2003 - 11/2001
2Histocompatibility Antigens Class IIIBA
04/2002 - 02/2001
2human CHI3L1 proteinIBA
12/2000 - 07/2000
1cartilage matrix proteinIBA
06/2008
1Rheumatoid FactorIBA
05/2008
1Interleukin-1 Receptors (Interleukin 1 Receptor)IBA
08/2007
1rituximab (Mabthera)FDA Link
02/2007
1GTP Phosphohydrolases (GTPases)IBA
10/2006
1Reactive Oxygen Species (Oxygen Radicals)IBA
10/2006
1MicronutrientsIBA
06/2004
1Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA
06/2004
1AutoantibodiesIBA
03/2004
1Antirheumatic Agents (DMARD)IBA
12/2003
1CytokinesIBA
07/2003
1Matrix MetalloproteinasesIBA
07/2003
1Tranexamic Acid (AMCA)FDA Link
05/2003
1Plasmin (Fibrinolysin)FDA Link
05/2003
1Leucovorin (Folinic Acid)FDA LinkGeneric
07/2001
1Interleukin-8 (Interleukin 8)IBA
01/2001
1CitrullineIBA
01/2001
1Proteoglycans (Proteoglycan)IBA
01/2001
1Calcitriol (Calcijex)FDA LinkGeneric
12/2000
1Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA
05/2000
1Bacterial DNAIBA
03/2000
1Metalloproteases (Metalloproteinases)IBA
02/2000
1Interferon-betaIBA
02/2000
1Nitric Oxide (Nitrogen Monoxide)FDA Link
01/2000
1HLA-DR3 Antigen (HLA DR3 Antigen)IBA
01/2000
1Antigen-Antibody Complex (Immune Complex)IBA
01/2000

Therapy/Procedure

3Stem Cell Transplantation
08/2004 - 06/2001
2Drug Therapy (Chemotherapy)
08/2005 - 04/2001
2Hematopoietic Stem Cell Transplantation
08/2005 - 04/2001
1Musculoskeletal Manipulations (Manipulative Therapy)
04/2005
1Aftercare (After-Treatment)
01/2005